Table 2. Percentage (95% CI) of facilities with tests and medicines for screening, diagnosis and management of diseases available, by healthcare facility type.
| IHC (N = 79) | DH (N = 22) | MCH (N = 9) | All (N = 110) | |
|---|---|---|---|---|
| Diagnostic tests | ||||
| HIV rapid test | 91 [82–96] | 100 [100–100] | 78* | 92 [84–96] |
| HIV lab test | 7 [3–16] | 79 [52–93] | 100* | 14 [9–21] |
| Rapid diagnostic test for syphilis | 13 [8–23] | 92 [70–98] | 100* | 21 [14–29] |
| Sputum tests for TB | 34 [25–46] | 100 [100–100] | 22* | 39 [29–49] |
| Rapid diagnostic test for malaria | 99 [91–100] | 72 [47–88] | 78* | 96 [92–98] |
| Thick blood smear | 10 [5–18] | 97 [78–100] | 100* | 17 [12–25] |
| Haemoglobin test | 13 [7–22] | 79 [55–92] | 100* | 19 [13–27] |
| Urine analysis (dip stick) | 54 [43–65] | 100 [100–100] | 89* | 58 [48–68] |
| Medicines for prevention and management of infectious diseases | ||||
| ARV first line combination for HIV | 28 [19–38] | 91 [66–98] | 89* | 33 [25–43] |
| HRZE quadritherapy for TB | 36 [26–46] | 94 [76–99] | 0* | 39 [30–49] |
| Sulfadoxine pyrimethamine | 91 [83–96] | 67** | 100* | 91 [83–96] |
| ACT or artesunate/arthemeter IM | 91 [83–96] | 89 [68–97] | 100* | 91 [84–96] |
| Quinine | 91 [82–96] | 77 [51–91] | 89* | 90 [82–95] |
| Benzathine benzyl penicillin injection | 69 [58–79] | 56 [35–75] | 67* | 68 [58–77] |
| Amoxicillin or Ampicillin | 88 [79–94] | 95 [70–99] | 89* | 89 [80–94] |
| Gentamicin | 78 [68–86] | 71 [48–87] | 78* | 78 [68–85] |
| Metronidazole | 86 [76–92] | 92 [68–98] | 100* | 87 [78–92] |
| Acyclovir | 17 [10–26] | 55 [31–76] | 78* | 21 [14–29] |
| Albendazole/Mebendazole | 86 [76–92] | 77 [53–90] | 67* | 85 [76–91] |
| Medicines for EmONC | ||||
| Injectable oxytocin | 98 [91–99] | 100 [100–100] | 100* | 98 [91–99] |
| Calcium gluconate | 43 [33–54] | 69 [45–86] | 89* | 46 [36–55] |
| Magnesium sulphate | 89 [79–94] | 95 [70–99] | 100* | 89 [81–94] |
| Diazepam | 86 [77–92] | 85 [59–96] | 100* | 86 [78–92] |
| Corticosteroid (prednisolone/dexamethasone) | 82 [72–89] | 90 [65–98] | 89* | 83 [73–90] |
| Ringer Lactate or NaCL 0.9% | 88 [79–94] | 100 [100–100] | 100* | 89 [81–94] |
| Vaccines | ||||
| Tetanus toxoid vaccine | 96 [89–99] | 100** | 50* | 96 [89–99] |
| BCG vaccine | 92 [84–97] | 83 [57–95] | 89* | 92 [84–96] |
| Vaccine against measles | 96 [89–99] | 75 [50–90] | 22* | 93 [88–97] |
| Oral polio vaccine | 99 [92–100] | 80 [55–93] | 67* | 97 [93–99] |
| Penta vaccine | 99 [92–100] | 72 [48–88] | 11* | 95 [91–98] |
| Vaccine against Rotavirus | 99 [92–100] | 75 [50–90] | 11* | 96 [92–98] |
| Vaccine against pneumococcus | 93 [85–97] | 70 [46–87] | 11* | 90 [83–94] |
| Vaccine against meningococcus | 54 [43–64] | 50 [29–71] | 11* | 53 [43–62] |
*No CI provided as statistics are without error and reflect true value (all existent MCH nationwide are included in the sample)
** Sample size did not allow generation of 95% CIs, due to healthcare facilities reporting the service was not applicable to their facility
N = number of facilities
IHC = Integrated Health Centres, DH = District Hospitals, MCH = Mother and Child Hospitals, HIV = Human Immunodeficiency Virus, TB = Tuberculosis, ARV = Antiretroviral drugs, HRZE = Isoniazid + Rifampin + Pyrazinamide + Ethambutol quadritherapy, ACT = Artemisin-based Combination Therapy, BCG = Bacillus Calmette-Guerin, EmONC = Emergency Obstetric and Newborn Care